



## The role of mitochondrial derived peptides (MDPs) in metabolism

Journal:	<i>Journal of Cellular Physiology</i>
Manuscript ID:	JCP-15-0135.R1
Wiley - Manuscript type:	Letter to the Editor
Date Submitted by the Author:	n/a
Complete List of Authors:	Alis, Rafael; Catholic University of Valencia, Research Institute "Dr. ViñaGiner", Molecular and Mitochondrial Medicine; C, S Lucia, Alejandro; Universidad Europea and Research Institute of Hospital 12 de Octubre, Sanchis-Gomar, Fabian; Research Institute of Hospital 12 de Octubre ("i+12"), Blesa, Jose; Catholic University of Valencia San Vicente Mártir, School of Medicine; Catholic University of Valencia San Vicente Mártir, Research Institute "Dr. Viña Giner", Molecular and Mitochondrial Medicine
Key Words:	Mitochondria, Insulin resistance, Obesity

SCHOLARONE™  
Manuscripts

view

1  
2  
3  
4 **1 The role of mitochondrial derived peptides (MDPs) in**  
5  
6 **2 metabolism**  
7  
8  
9  
10

11 **4 Authors:** Rafael Alis<sup>1,2\*</sup>, Alejandro Lucia<sup>3,4</sup>, Jose R Blesa<sup>1,2</sup>, Fabian Sanchis-Gomar<sup>3\*</sup>  
12  
13

14 1. Research Institute “Dr. ViñaGiner”, Molecular and Mitochondrial Medicine. Catholic  
15 University of Valencia San Vicente Mártir, Valencia, Spain.  
16

17 2. School of Medicine, Catholic University of Valencia San Vicente Mártir, Valencia, Spain.  
18

19 3. Research Institute of Hospital 12 de Octubre (“i+12”), Madrid, Spain.  
20

21 4. European University, Madrid, Spain.  
22

23 \*These authors equally contributed to this work.  
24

25 **13 Manuscript type:** Commentary  
26  
27

28 **15 Word count:** 753 words  
29  
30

31 **17 Corresponding author**  
32

33 Rafael Alis  
34

35 Research Institute “Dr. ViñaGiner”, Molecular and Mitochondrial Medicine  
36

37 Catholic University of Valencia San Vicente Mártir,  
38

39 C/ Quevedo 2, 46001 Valencia, Spain  
40

41 E-mail: rafael.alis@ucv.es  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 25 The term “mitokines” refers to signals derived from mitochondria that have an impact  
5  
6 26 on other cells or tissues (Durieux et al., 2011). Rather than being simply a set of DNA  
7  
8 27 composed by 37 genes, the mitochondrial DNA (mtDNA) is quite complex and includes  
9  
10 28 small RNAs (Mercer et al., 2011). Mitochondrial-derived peptides (MDPs) are encoded  
11  
12 29 by functional short open reading frames (sORFs) in the mtDNA. Until very recently,  
13  
14 30 humanin, a 24-amino-acid peptide encoded in the 16S rRNA region with strong  
15  
16 31 cytoprotective effects against various stresses and diseases (Hashimoto et al., 2001),  
17  
18 32 was the only recognized MDP. Lee et al have recently reported another MDP, named  
19  
20 33 *mitochondrial open reading frame of the 12S rRNA-c* (MOTS-c), which regulates  
21  
22 34 insulin sensitivity and metabolic homeostasis (Lee et al., 2015).  
23

24  
25 35 The peroxisome proliferator-activated receptor  $\gamma$  coactivator-1 $\alpha$  (PGC-1 $\alpha$ ) is a master  
26  
27 36 modulator of metabolism, with a key function in mitochondrial biogenesis (Sanchis-  
28  
29 37 Gomar et al., 2014). A PGC-1 $\alpha$ -related activator that is currently regarded as a putative  
30  
31 38 molecular target to mitigate excess adiposity and insulin resistance is the 5' AMP-  
32  
33 39 activated protein kinase (AMPK) (Price et al., 2012). CNX-012-570, a compound with a  
34  
35 40 highly potent AMPK-activating effect, improves insulin sensitivity and reduces body  
36  
37 41 weight gain (Anil et al., 2014). MOTS-c targets the folate cycle thereby reducing *de*  
38  
39 42 *novo* purine biosynthesis, which results in accumulation of 5-amino-1- $\beta$ -D-  
40  
41 43 ribofuranosyl-imidazole-4-carboxamide (AICAR) and subsequent AMPK activation  
42  
43 44 (Lee et al., 2015). Therefore, a positive feed-forward loop could be hypothesized,  
44  
45 45 involving MOTS-c production in mitochondria, cellular AICAR accumulation and  
46  
47 46 AMPK activation, followed by PGC-1 $\alpha$  phosphorylation and subsequent enhanced  
48  
49 47 mitochondrial biogenesis, which in turn would increase MOTS-c production.  
50

51  
52 48 The effect of MOTS-c on the AMPK axis can affect glucose homeostasis, e.g., MOTS-c  
53  
54 49 infused mice show protection against insulin resistance and obesity induced by a high-  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 50 fat diet (Lee et al., 2015). Although strategies targeting the AICAR-AMPK axis are not  
5  
6 51 new, MOTS-c could be a more suitable pharmacological target since Lee et al showed  
7  
8 52 that a highly metabolic tissue, such as the skeletal muscle, is the key target site for the  
9  
10 53 activity of this mytokine (Lee et al., 2015). Therefore, MOTS-c acts directly on the  
11  
12 54 muscle tissue, where therapies for insulin resistance are likely to exert the strongest  
13  
14 55 possible effect. In addition, liver toxicities induced by drugs like metformin, AICAR or  
15  
16 56 methotrexate could be avoided, emphasizing the great potential of MOTS-c as a target  
17  
18 57 for novel therapies.

19  
20  
21 58 The findings presented by Lee et al show that MDPs play a role in whole-body  
22  
23 59 metabolic balance in mice, which highlights the importance of mitochondria not just as  
24  
25 60 end-point fat burners but also as key players in endocrine regulation. Interestingly, the  
26  
27 61 protection conferred by MOTS-c against the deleterious effects of a high-fat diet shares  
28  
29 62 many similarities with that provided by regular exercise (Tofolo et al., 2014). The  
30  
31 63 stimuli elicited by exercise induce phenotype modifications at the skeletal muscle level  
32  
33 64 that increase oxidative capacity and fat utilization while reducing lipid-mediated insulin  
34  
35 65 resistance (Samuel and Shulman, 2012). One of the key factors in the skeletal muscle  
36  
37 66 reprogramming induced by regular exercise is activation of the PGC-1 $\alpha$  axis, leading to  
38  
39 67 increased mitochondrial biogenesis, and hence, higher mitochondrial content. In fact, a  
40  
41 68 broad range of PGC-1 $\alpha$ -related target activators represent a promising opportunity for  
42  
43 69 treatment of ectopic lipid accumulation ('lipotoxicity') and insulin resistance, which are  
44  
45 70 also under current investigation (Srivastava et al., 2012). It is also possible that aging  
46  
47 71 might reduce mitochondrial activity and MDPs expression while regular exercise would  
48  
49 72 have the opposite, 'anti-aging' effect (**Figure 1**). According to this point of view,  
50  
51 73 exercise could enhance the endocrine and paracrine action of skeletal muscle-derived  
52  
53 74 MDPs such as MOTS-c.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 75 Lee et al have identified a mitokine that is potentially associated with metabolic  
5  
6 76 diseases such as diabetes and obesity. This newly discovered mitokine could also play  
7  
8 77 an important role in the pathophysiology of aging-related diseases, since, along with  
9  
10 78 mitochondrial dysfunction, reduced expression of MDPs could be responsible, at least  
11  
12 79 partly, for the metabolic imbalance driven by aging (Lee et al., 2015). Interestingly, the  
13  
14 80 potential role of MOTS-c in regulating other biological functions, including perhaps  
15  
16 81 metabolism in cancer cells (by virtue of its inhibiting effect on *de novo* purine  
17  
18 82 synthesis), remains to be studied.

19  
20  
21 83 MOTS-c activity and its role in regulating metabolism should be confirmed and better  
22  
23 84 understood (particularly, the putative upstream factors regulating MOTS-c expression)  
24  
25 85 to develop safe and useful drugs to counter obesity and related diseases. A key  
26  
27 86 challenge is to determine whether MOTS-c could be similarly modulated in humans as  
28  
29 87 well as to establish its therapeutic potential. Once these knowledge gaps are filled, the  
30  
31 88 use of mitokines for therapeutic purposes could become a realistic option.

### 32 33 34 35 36 37 89 **Funding**

38  
39 90 This research has been supported by grant DEP2012-37494 from the Spanish  
40  
41 91 Government and by grants 2013-168-002 and 2014-168-001 from Catholic University  
42  
43 92 of Valencia. RA is predoctoral fellow of Catholic University of Valencia.

### 44 45 46 93 **Conflict of interests**

47  
48 94 The authors declare no conflict of interests.  
49  
50 95

### 51 52 53 96 **References**

54  
55 97 Anil TM, Harish C, Lakshmi MN, Harsha K, Onkaramurthy M, Sathish Kumar V,  
56  
57 98 Shree N, Geetha V, Balamurali GV, Gopala AS, Madhusudhan Reddy B,

- 1  
2  
3  
4 99 Govind MK, Anup MO, Moolemath Y, Venkataranganna MV, Jagannath MR,  
5  
6 100 Somesh BP. 2014. CNX-012-570, a direct AMPK activator provides strong  
7  
8 101 glycemc and lipid control along with significant reduction in body weight;  
9  
10 102 studies from both diet-induced obese mice and db/db mice models. Cardiovasc  
11  
12 103 Diabetol 13:27.  
13  
14  
15  
16  
17 104 Durieux J, Wolff S, Dillin A. 2011. The cell-non-autonomous nature of electron  
18  
19 105 transport chain-mediated longevity. Cell 144(1):79-91.  
20  
21  
22  
23 106 Hashimoto Y, Niikura T, Tajima H, Yasukawa T, Sudo H, Ito Y, Kita Y, Kawasumi M,  
24  
25 107 Kouyama K, Doyu M, Sobue G, Koide T, Tsuji S, Lang J, Kurokawa K,  
26  
27 108 Nishimoto I. 2001. A rescue factor abolishing neuronal cell death by a wide  
28  
29 109 spectrum of familial Alzheimer's disease genes and Abeta. Proc Natl Acad Sci U  
30  
31 110 S A 98(11):6336-6341.  
32  
33  
34  
35  
36 111 Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H,  
37  
38 112 Hevener AL, de Cabo R, Cohen P. 2015. The Mitochondrial-Derived Peptide  
39  
40 113 MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin  
41  
42 114 Resistance. Cell Metab 21(3):443-454.  
43  
44  
45  
46  
47 115 Mercer TR, Neph S, Dinger ME, Crawford J, Smith MA, Shearwood AM, Haugen E,  
48  
49 116 Bracken CP, Rackham O, Stamatoyannopoulos JA, Filipovska A, Mattick JS.  
50  
51 117 2011. The human mitochondrial transcriptome. Cell 146(4):645-658.  
52  
53  
54  
55  
56 118 Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, Agarwal B,  
57  
58 119 Ye L, Ramadori G, Teodoro JS, Hubbard BP, Varela AT, Davis JG, Varamini B,  
59  
60

*Manuscript resubmitted to Journal of Cellular Physiology*

1  
2  
3  
4 120 Hafner A, Moaddel R, Rolo AP, Coppari R, Palmeira CM, de Cabo R, Baur JA,  
5  
6 121 Sinclair DA. 2012. SIRT1 is required for AMPK activation and the beneficial  
7  
8 122 effects of resveratrol on mitochondrial function. *Cell Metab* 15(5):675-690.  
9

10  
11  
12  
13 123 Samuel VT, Shulman GI. 2012. Mechanisms for insulin resistance: common threads  
14  
15 124 and missing links. *Cell* 148(5):852-871.  
16

17  
18  
19 125 Sanchis-Gomar F, Garcia-Gimenez J-L, Gomez-Cabrera M-C, Pallardo F. 2014.  
20  
21 126 Mitochondrial Biogenesis in Health and Disease. *Molecular and Therapeutic*  
22  
23 127 Approaches. *Curr Pharm Des* 20(35):5619-5633.  
24

25  
26  
27 128 Srivastava RA, Pinkosky SL, Filippov S, Hanselman JC, Cramer CT, Newton RS. 2012.  
29  
30 129 AMP-activated protein kinase: an emerging drug target to regulate imbalances in  
31  
32 130 lipid and carbohydrate metabolism to treat cardio-metabolic diseases. *J Lipid*  
33  
34 131 Res 53(12):2490-2514.  
35

36  
37  
38 132 Tofolo LP, da Silva Ribeiro TA, Malta A, Miranda RA, Gomes RM, de Oliveira JC,  
39  
40 133 Abdennebi-Najar L, de Almeida DL, Trombini AB, da Silva Franco CC,  
41  
42 134 Pavanello A, Fabricio GS, Rinaldi W, Barella LF, de Freitas Mathias PC, Palma-  
43  
44 135 Rigo K. 2014. Short-term moderate exercise provides long-lasting protective  
45  
46 136 effects against metabolic dysfunction in rats fed a high-fat diet. *Eur J Nutr*.  
47  
48

49  
50  
51 137 **Figure legend**

52  
53  
54 138 **Figure 1.** Schematic representation of the role of MOTS-c in metabolism and possible  
55  
56 139 effects of exercise (blue) and aging (red) on the MOTS-c – AMPK axis. Abbreviations:  
57  
58  
59  
60

*Manuscript resubmitted to Journal of Cellular Physiology*

1  
2  
3  
4 140 AICAR, 5-amino-1- $\beta$ -D-ribofuranosyl-imidazole-4-carboxamide; AMPK, 5' AMP-  
5  
6 141 activated protein kinase; MOTS-c, mitochondrial open reading frame of the 12S rRNA-  
7  
8 142 c; mtDNA, mitochondrial DNA; PGC-1 $\alpha$ , peroxisome proliferator-activated receptor  $\gamma$   
9  
10 143 coactivator-1 $\alpha$ .

11  
12  
13  
14 144  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review






Figure 1. Schematic representation of the role of MOTS-c in metabolism and possible effects of exercise (blue) and aging (red) on the MOTS-c - AMPK axis. Abbreviations: AICAR, 5-amino-1- $\beta$ -D-ribofuranosyl-imidazole-4-carboxamide; AMPK, 5' AMP-activated protein kinase; MOTS-c, mitochondrial open reading frame of the 12S rRNA-c; mtDNA, mitochondrial DNA; PGC-1 $\alpha$ , peroxisome proliferator-activated receptor  $\gamma$  coactivator-1 $\alpha$ .  
90x52mm (300 x 300 DPI)